Trial · NCT06890624
mFOLFOXIRI Plus PD-1 Inhibitor vs mFOLFOX6 as Neoadjuvant Therapy for Locally Advanced Colon Cancer
NCT06890624, Phase 2, Not yet recruiting, Sun Yat-sen University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. mFOLFOXIRI Plus PD-1 Inhibitor vs mFOLFOX6 as Neoadjuvant Therapy for Locally Advanced Colon Cancer. Trials, record NCT06890624. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06890624
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- mFOLFOXIRI Plus PD-1 Inhibitor vs mFOLFOX6 as Neoadjuvant Therapy for Locally Advanced Colon Cancer
- NCT number
- NCT06890624
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 138 participants, estimated
- Lead sponsor
- Sun Yat-sen University
- Conditions
- Colon Cancer (Stage II &Amp;Amp; III)
- Interventions
- cmFOLFOXIRI plus PD-1 inhibitor, mFOLFOX6
- First posted
- 2025-03-24
- Last updated
- 2026-05-22
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pathologic complete response rate | 1 year | The percentage of subjects with no residual viable tumor in the resected primary tumor specimen and all sampled regional lymph nodes after radical surgery (ypT0N0). |
| Secondary | R0 resection rate | 1 year | The proportion of patients whose tumors are completely removed without residual cancer cells under the microscope. None of the following conditions can be considered as R0 resection: non-complete resection of the tumor, positive circumferential, proximal, or distal resection margin (resection margin of \>1 mm). |
| Secondary | Event-free survival (EFS) | 3 years | The time between randomization and one of the following events: locally progressive disease leading to an unresectable tumor, local R2 resection, local recurrence after an R0/1 resection, distant metastases, a new primary colorectal cancer, or death from any cause, whichever occurred first. |
| Secondary | Disease-free survival (DFS) | 3 years | The time from the date of surgery to the date of locoregional recurrence, distant metastases, a new primary colorectal cancer, or death from any cause, whichever occurred first. |
| Secondary | Overall survival (OS) | 5 years | The time from randomization to death from any cause. Subjects who are still alive at the time of the analysis will be censored for OS on the latest known survival date. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06890624
GET https://conductscience.org/api/trials/v1/NCT06890624/registered